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ttp://dx.doi.org/10.1016/j.ajpath.2013.07.016Fibrosis is characterized by accumulation of activated ﬁbroblasts and pathological deposition of ﬁbrillar
collagens. Activated ﬁbroblasts overexpress matrix proteins and release factors that promote further
recruitment of activated ﬁbroblasts, leading to progressive ﬁbrosis. The contribution of epithelial cells
to this process remains unknown. Epithelium-directed injury may lead to activation of epithelial cells
with phenotypes and functions similar to activated ﬁbroblasts. Prior reports that used a reporter gene
fate-mapping strategy are limited in their ability to investigate the functional signiﬁcance of epithelial
cell-derived mesenchymal proteins during ﬁbrogenesis. We found that lung epithelial cell-derived
collagen I activates ﬁbroblast collagen receptor discoidin domain receptor-2, contributes signiﬁcantly
to ﬁbrogenesis, and promotes resolution of lung inﬂammation. Alveolar epithelial cells undergoing
transforming growth factor-bemediated mesenchymal transition express several other secreted proﬁ-
brotic factors and are capable of activating lung ﬁbroblasts. These studies provide direct evidence that
activated epithelial cells produce mesenchymal proteins that initiate a cycle of ﬁbrogenic effector cell
activation, leading to progressive ﬁbrosis. Therapy targeted at epithelial cell production of type I
collagen offers a novel pathway for abrogating this progressive cycle and for limiting tissue ﬁbrosis but
may lead to sustained lung injury/inﬂammation. (Am J Pathol 2013, 183: 1559e1570; http://
dx.doi.org/10.1016/j.ajpath.2013.07.016)Supported by NIH grants R01 HL108904 (K.K.K.), K08 HL085290
(K.K.K.), and RO1 HL44712 (H.A.C.).Progressive ﬁbrosis can occur as a serious complication
of lung injury, as a sequel of many inﬂammatory chronic
diseases, or as a primary disease, such as idiopathic pulmo-
nary ﬁbrosis (IPF).1 Progressive ﬁbrosis often has a devas-
tating clinical course without good therapeutic options.
Tissue ﬁbrosis is characterized by accumulation of activated
ﬁbroblasts and extensive matrix remodeling. Primary func-
tions of activated ﬁbroblasts include deposition of ﬁbrotic
matrix proteins and secretion of proﬁbrotic factors.1e4 The
cellular source of activated ﬁbroblasts remains unknown and
controversial.5 The traditional model has been that resident
ﬁbroblasts respond to injury by proliferating and acquiring
a proﬁbrotic, activated phenotype accounting for all of the
deposition of ﬁbrotic matrix proteins. A newer hypothesis
is that structural cells with normal physiological functions
can respond to injury by down-regulating some of their
physiological proteins and activities in favor of a proﬁbroticstigative Pathology.
.phenotype that overlaps with activated ﬁbroblast activities.
Proposed cells that can respond in this way include epithelial
cells, endothelial cells, and pericytes. A third possible source
of ﬁbrillar collagens are from circulating bone marrow-
derived ﬁbrocytes that can be rapidly recruited to sites of
injury. These different possibilities are not mutually exclu-
sive and may potentially have nonredundant functions during
ﬁbrogenesis.5e9 In addition to the secretion of ﬁbrotic matrix
proteins, activated ﬁbroblasts have an important function in
recruiting more activated ﬁbroblasts through secretion of
speciﬁc proﬁbrotic factors in response to transforming
growth factor (TGF)-bemediated activation.2,5 Thus, a
proposed model is that injury leads to activation of structural
lung cells toward a proﬁbrotic phenotype similar to activated
Yang et alﬁbroblasts, leading to early ﬁbrotic matrix deposition and
activation of other proﬁbrotic effector cells. Understanding
these events may lead to new targets for inhibiting progres-
sive ﬁbrogenesis.
Activation of lung epithelial cells during ﬁbrogenesis is an
attractive hypothesis, given the likely propensity for envi-
ronmental lung epithelial injury and the extensive animal
model and human data suggesting that epithelial cell dys-
regulation is an important contributor of lung ﬁbro-
genesis.10e13 We and others have identiﬁed expression of
mesenchymal genes, such as type I collagen, within epithelial
cells of human ﬁbrotic lung tissue, suggesting partial
mesenchymal transition.14e16 A number of different lung
epithelial cells, including alveolar and airway epithelial cells,
can undergo epithelial-mesenchymal transitions (EMTs)
in vitro in response to cytokines known to be highly
expressed in the ﬁbrotic lung.17e20 Fate-mapping studies that
use an epithelial cell-speciﬁc Cre transgene and a lox-stop-
lox reporter transgene to permanently and speciﬁcally label
epithelial cells were proposed as a deﬁnitive method for
proving or disproving EMTs during animal models of
ﬁbrogenesis.21 However, these studies have severe limita-
tions leading to continued controversy.22 For example, in the
lung at least three separate groups have identiﬁed EMTs
during ﬁbrogenesis by this technique, although a recent
report failed to ﬁnd evidence of EMTs.23e26 A similar
controversy exists in ﬁbrogenesis of the kidney and
liver.6,21,22,27e29 One of the points of controversy has been
the potential for artifact from overlapping cells, leading to the
appearance of a cell costaining the reporter protein and
a mesenchymal protein. The costaining approach lends itself
to cytoskeletal or cell surface protein such as vimentin,
a-smooth muscle actin (SMA), ﬁbroblast-speciﬁc protein, or
N-cadherin, but these proteins are of uncertain functional
signiﬁcance to ﬁbrogenesis. Most importantly, gene expres-
sion studies in human samples and the murine fate-mapping
reporter gene costaining approaches are both ultimately
descriptive without addressing these more important ques-
tions: to what extent and in what way do different cell types
contribute to ﬁbrosis? Several recent reports have found that
epithelial cell-speciﬁc deletion of EMT transcription factors
and cell surface receptors can dramatically attenuate ﬁbrosis
well beyond the fractional contribution of epithelial-derived
cells to the pool of activated ﬁbroblasts, suggesting that
activated epithelial cells may have a nonredundant function
during ﬁbrogenesis.30e33
The present study offers a new and more functional
approach to understanding the contribution of epithelial
cells. We have developed a novel mouse model with con-
ditional deletion of type I collagen that enables lung
epithelial cell-speciﬁc deletion of this gene to determine the
ultimate consequences on ﬁbrogenesis. In addition to type I
collagen, we found that activated lung epithelial cells ex-
press a number of proﬁbrotic proteins and can activate lung
ﬁbroblasts. These studies conﬁrm an early and important
epithelial cell expression of type I collagen and shift the1560focus away from arbitrary deﬁnitions of EMTs to better
understanding the function of epithelial cells during
ﬁbrogenesis.
Materials and Methods
Mice
The ﬂoxed collagen, type I, alpha 1 (Col1a1) targeting
vector was generated with standard cloning and recombin-
eering techniques to incorporate loxP sites within introns 2
and 5 and a FRT [ﬂippase (Flp) recombination target]-
ﬂanked neomycin resistance gene within intron 5
(Supplemental Figure S1). Embryonic stem (ES) cell elec-
troporation, ES cell culture, and blastocyst injection to
generate chimera were performed by inGenious Targeting
Laboratory (Ronkonkoma, NY). ES clones were screened
by PCR and Southern blot analysis. Southern blot analysis
was performed as previously described.34 ES cell DNA was
digested with SphI and 50 probe that was generated with the
following primers: forward, 50-AATAGTGTTATGCTCT-
GGTTTC-30 and reverse, 50-CTGCAGTGGCTAGAAAA-
GTCA-30. The 50 probe recognizes a 23-kb DNA fragment
for wild-type (WT) ES cells and a 15-kb fragment for
correctly targeted ﬂoxed Col1a1 ES cells. ES cell DNA also
was digested with HindIII and 30 probe generated with the
following primers: forward, 50-CTGGTCGCCCCGGTGA-
30 and reverse, 50-GACTTGGGTGTGACTATCACATA-
AAAAGACC-30. The 30 probe recognizes a 10-kb DNA
fragment for WT ES cells and a 5-kb DNA fragment for
correctly targeted ﬂoxed Col1a1 ES cells. For PCR analysis
of ﬂoxed Col1a1, forward primer (F1), 50-ATCCATCAT-
GGCTGATGCAATGCG-30, located with neomycin resis-
tance and reverse primer (R1), 50-TGACTTACGGGTTCT-
CCTTTGGCA-30, located 7 kb from the start site conﬁrm
integration of targeting vector to the Col1a1 gene. Forward
primer (F2), 50-GGTAGCTCTGGCATGCATAAC-30, over-
laps with 50 loxP site and reverse (R2), 50-AGCTAGCTT-
GGCTGGACGTAAACT-30, within neomycin resistance
conﬁrm integration of the 50 loxP site and neomycin gene on
the same allele. Forward primer (F3), 50-TGGTACAGCA-
CTTTACAGCGCACA-30, located upstream of 50 loxP in-
sertion site and reverse prime (R3), 50-TTACTCGGCCTGG-
GTCACTTCTTT-30, are located downstream of 50 loxP
insertion site; WT allele yields a 138-bp PCR product, ﬂoxed
Col1a1 with insertion of 40-bp loxP, and SphI site yields
a 178-bp band. Removal of neomycin gene conﬁrmed by
PCR using forward primer (F4), 50-ACTGTCCTCCAATA-
AACTGCAGTTTTCTTT-30, located upstream of neomycin
insertion site and reverse primer (R4), 50-TAGCAGTAAT-
GGGACAAACGGATGTAG-30, located downstream of
neomycin insertion site. Mice with constitutive expression
of ﬂpE (The Jackson Laboratory, Bar Harbor, ME) were used
to delete the FRT-ﬂanked neomycin resistance gene. Floxed
Col1a1 mice were backcrossed with C57bl/6 mice for at least
eight generations.ajp.amjpathol.org - The American Journal of Pathology
AEC-Derived Collagen I Promotes FibrosisTo delete ﬂoxed Col1a1 in lung epithelial cells mice were
crossed with mice expressing the surfactant proteins-C
promoter-reverse tetracycline transactivator (SPC-rtTA)
and tetO-CMV (cytomegalovirus) promoter-Cre recombi-
nase (tetO-Cre) transgenes as previously described.24 Triple
transgenic SPC-rtTA/tetO-Cre/Col1a1f/f (homozygous ﬂoxed
Col1a1) mice are abbreviated SCcol. Smad3-null mice were
purchased from The Jackson Laboratory (Bar Harbor, ME).
Mice were genotyped by PCR. Six- to 8-week-old mice were
given 50-mL intratracheal injections of saline or saline with
dissolved bleomycin (1.3 U/kg) via surgical tracheotomy. At
various time points after injection, mice were euthanized, and
bronchoalveolar lavage (BAL) and lung samples were
collected for analysis. For BAL, the lungs were lavaged with 1
mL of PBS per mouse. Samples were centrifuged, and the
supernatants were used for total protein count and immunoblot
analysis. The cell pellets were resuspended for total cell
counting with a hemocytometer under light microscopy. Lung
physiological measurements were obtained from 6- to 8-week-
old anesthetized SCcol mice and littermate controls as previ-
ously described.32,35
All mice were bred and maintained in a speciﬁc pathogen-
free environment, and all animal experiments were approved
by the University Animal Care and Use Committee at the
University of Michigan.
Reagents
Plasma ﬁbronectin (FN), bleomycin, and phospho-Smad2
antibody were purchased from Millipore (Billerica, MA);
collagen I, Matrigel (MG), biotin-conjugated rat anti-mouse
CD16/32 and CD45 antibodies, and 70-mm and 40-mm nylon
ﬁlters from BD Biosciences (San Jose, CA); puriﬁed human
keratinocyte growth factor from PeproTech (Rocky Hill, NJ);
puriﬁed human TGF-b1 from R&D Systems (Minneapolis,
MN); small airway basal media and small airway growth
media (SAGM) from Lonza Inc. (Allendale, NJ); horseradish
peroxidase-conjugated secondary antibodies from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA); immunoﬂuorescent-
conjugated secondary antibodies, streptavidin-coated mag-
netic beads, and magnetic particle separator from Invitrogen
(Carlsbad, CA); collagen I and discoidin domain receptor-2
(DDR2) antibodies from Abcam (Cambridge, MA); horse-
radish peroxidase-conjugated phospho-tyrosine and glycer-
aldehyde phosphate dehydrogenase (GAPDH) antibodies
from Cell Signaling Technology Inc. (Danvers, MA);
adenoviruses expressing Cre (AdCre) or green ﬂuorescent
protein (AdGFP) were obtained from the University of Iowa
Gene Transfer Vector Core Facility; and dispase from Roche
(Indianapolis, IN). All other reagents were purchased from
Sigma-Aldrich (St. Louis, MO).
Mouse Fibroblast and Type II Cell Isolation and Culture
Cells were cultured in a 37C, 5% CO2 incubator. Murine
primary lung ﬁbroblasts were harvested from 6- to 10-week-oldThe American Journal of Pathology - ajp.amjpathol.orgmice as described previously.36 Cells were used at passages
two to four. In some experiments cells were treated with three
daily doses of AdGFP or ADCre (50 pfu/cell) and then
cultured for an additional 7 days before analyzing the cells.
Adult murine ﬁbroblast cell line, MLg (CCL-206), was
purchased from the American Type Culture Collection
(Manassas, VA) and also maintained in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) with 10% fetal bovine serum,
penicillin, and streptomycin.Murine type II alveolar epithelial
cells (AECs) were isolated as previously describedwith minor
modiﬁcations.24,37 Brieﬂy, after mice were sacriﬁced, lungs
were exposed, perfused, and lavaged. Lungs were ﬁlled with
dispase, followed by low-melt agarose. Lungs were digested
at room temperature for 45 minutes then dissected. Dissected
lungs were then treated with DNase for 10 to 15 minutes, then
serially ﬁltered through 70-mm, 40-mm, and 20-mm ﬁlters. The
crude suspensions were then labeled for CD16/32 and CD45
with the use of biotin-conjugated antibodies, streptavidin-
conjugated magnetic beads, and a magnetic separator.
AECs were further negatively selected by incubating for 1 to
2 hours on a tissue-cultureetreated plastic plate.
H&E Staining and Masson’s Trichrome Assay
Lungs from sacriﬁced mice were inﬂated to a pressure of
25 cm H2O and ﬁxed with formaldehyde. Lungs were
embedded in parafﬁn, sectioned, and stained with H&E and
Masson’s trichrome by the McClinchey Histology Labora-
tory (Stockbridge, MI).
Hydroxyproline Assay
Hydroxyproline was measured by methods previously de-
scribed.36 Brieﬂy, homogenates from the entire lungs were
baked in 12N HCl overnight at 120C. Aliquots of the
samples were added to citrate buffer and chloramine T
solution and incubated at room temperature for 20 minutes.
Erlich’s solution was added, and the samples were incubated
at 65C for 15 minutes. Absorbance at 540 nm was mea-
sured. Hydroxyproline content was quantiﬁed by comparison
against a hydroxyproline standard curve.
Immunoﬂuorescence Staining
Lungs were perfused with PBS, inﬂated with intratracheal
OCT, removed, and immediately frozen in a dry-ice alcohol
bath. Lungswere stored at80C. Seven-micron lung sections
were stained as previously described.24 Stained sections were
visualized on an Olympus BX-51 ﬂuorescence microscope
(Olympus, Tokyo, Japan), and images were captured with an
Olympus DP-70 camera and analyzed with DP controller
software version 3.1.1.267.
Collagen I Deletion in Fibroblasts
Col1a1f/f lungﬁbroblastswere treatedwith three daily doses of
AdGFP orAdCre (50 pfu/cell). After 1week equal numbers of1561
Yang et alcells were plated on tissue culture plastic or collagen I-coated
plates. Cells were maintained in DMEM and cultured on
collagen I-coated plates, whichwere treatedwith an additional
10 mg/mL collagen I. After 24 hours, RNA was collected for
gene expression analysis. In some experiments, AdCre-treated
Col1a1f/f ﬁbroblasts were seeded on six-well tissue culture
plates and then stimulatedwith 1mL ofDMEMsupplemented
with 0.5 mL of BAL ﬂuid from control and SCcol mice
collected 1 week after saline or bleomycin injury or treated
with 10mg/mL puriﬁed collagen I. After 15minutes cells were
lyzed and analyzed for DDR2 phosphorylation.
CM Stimulation
AECs were cultured on either MG- or FN-coated six-well
plates. Some wells were treated with 10 mmol/L TGF-b
receptor inhibitor SB431642, 5 pfu per cell lentivirus-
expressing siRNA, or 50 pfu/cell AdGFP or AdCre.
Conditioned media (CM) was generated by changing the
AEC media to serum-free SAGM plus 0.1% bovine serum
albumin 24 to 48 hours before collection (free of inhibitors
or lentivirus). Harvested CM was ﬁltered, then either stored
at 80C or immediately added to cultured lung ﬁbroblasts.
After 48 hours, ﬁbroblasts were lyzed for various assays.
Gene Expression Analysis
RNA was isolated from cells and tissue with TRIzol
Reagent (Invitrogen) according to the manufacturer. Re-
verse transcription was performed with the SuperScript III
First-strand synthesis kit (Invitrogen), and RT-PCR was
performed with POWER SYBR Green PCR MasterMix Kit
(Applied Biosystems, Foster City, CA) and Applied Bio-
systems 7000 sequence detection system. The relative
expression levels of gene were calculated against b-actin or
GAPDH. Eighty-four genes related to mouse ﬁbrosis plus
ﬁve housekeeping genes were evaluated by RT-PCR (RT2
Proﬁler PCR Arrays PAMM-120A; Qiagen, Valencia, CA)
according to the manufacturer. The gene expression level
was normalized to the average of ﬁve housekeeping genes
and was calculated as 2DDCt. PCR primers for ﬂoxed
Col1a1 DNA recombination were as follows: forward, 50-
GGTAGCTCTGGCATGCATAAC-30, and reverse, 50-AG-
CTAGCTTGGCTGGACGTAAACT-30. PCR of cDNA
isolated from whole lungs was used to detect the truncated
Col1a1 with forward primer 50-ATGGCCAAGAAGA-
CAAACTTT-30 (overlaps adjacent exon 1 and 6) and
reverse primer 50-GGCCTTGGAAACCTTGTGGAC-30.
RT-PCR was performed with the Power SYBR Green PCR
MasterMix Kit (Applied Biosystems). Relative expression
levels of genes in fold change were calculated against
b-actin or GAPDH. The following primers were used: col-
lagen 1a1, forward, 50-TGACTGGAAGAGCGGAGAG-
TACT-30, and reverse, 50-GGTCTGACCTGTCTCCATG-
TTG-30; connective tissue growth factor (CTGF), forward,
50-CACTCCGGGAAATGCTGCAAGGAG-30 and reverse,156250-GTTGGGTCTGGGCCAAATGT-30; collagen, type III,
alpha 1 (Col3a1), forward, 50-CAAGGTCTTCCTGGT-
CAGCCT-30 and reverse, 50-TGCCACCAGGAGATCCA-
TCTC-30; a-SMA, forward, 50-AGAGACTCTCTTCCAG-
CCATC-30 and reverse, 50-GACGTTGTTAGCATAGA-
GATC-30; b-actin, forward, 50-CCGTGAAAAGATGACC-
CAGATC-30 and reverse, 50-CACAGCCTGGATGGCTA-
CGT-30; GAPDH, forward, 50-AACTTTGGCATTGTGGA-
AGG-30 and reverse, 50-ACACATTGGGGGTAGGAACA-30.
Other primers used have been previously reported.38e41
Immunoblot Analysis
Immunoblot analysis and immunoprecipitation of tissue and
cells were performed as previously described.24 Scanned
immunoblots are representative of at least three separate
experiments, and densitometry was quantiﬁed by ImageJ
software version 1.47 (NIH, Bethesda, MD).
Statistical Analysis
Data were expressed as means  SEM. For evaluation of
group differences, the two-tailed Student’s t-test was used
assuming equal variance. A P value of <0.05 was accepted
as signiﬁcant.
Results
Generation and Validation of Mice with Lung Epithelial
Cell-Speciﬁc Deletion of Col1a1
Floxed Col1a1 mice were generated by integrating loxP sites
within introns 1 and 5 of the Col1a1 gene which enabled Cre-
mediated deletion of exons 2 to 5, resulting in frameshift and
early translational termination of the truncated mRNA
(Figure 1A and Supplemental Figure S1). Conditional deletion
of collagen I expression was conﬁrmed with the use of murine
embryonic ﬁbroblast (MEF) cells from Col1a1f/f embryos.
Col1a1f/f MEF cells treated with an AdCre had near complete
loss of collagen I compared with cells treated with a control
AdGFP or control MEFs (Col1a1w/w) treated with either
AdCre or AdGFP (Figure 1B and Supplemental Figure S2A).
Lung epithelial cell-speciﬁc recombination was achieved by
crossing with mice carrying the human SPC-rtTA and tetO-
CMV-Cre transgenes (Figure 1C).24 Recombination within
lung epithelial cells was veriﬁed with PCR primers encom-
passing the ﬂoxed region. DNA from lungs of SCcol mice
showed a 2.2-kb PCR product that corresponded to non-
recombined ﬂox Col1a1 in nonepithelial cells and a 0.5-kb
PCR product consistent with removal of the 1.7-kb ﬂoxed
region within epithelial cells. PCR of AECs from SCcol mice
yielded only the 0.5-kb recombined band, whereas PCR from
lung ﬁbroblasts yielded only the 2.2-kb non-recombined
band. DNA from littermate control mice, lacking one of the
transgenes, only produced the 2.2-kb PCR product. We and
others have previously reported that primary AECs cultured
on provisional matrix proteins such as FN undergo EMTsajp.amjpathol.org - The American Journal of Pathology
Figure 1 Generation and validation of mice with lung epithelial-speciﬁc deletion of Col1a1. A: Schematic of ﬂoxed Col1a1 (Col1a1f/f) mice generated by
inserting loxP sites ﬂanking exons 2 to 5 in the Col1a1 gene. Cre-mediated recombination of the ﬂoxed Col1a1 leads to removal of exons 2 to 5, shift in the
translational reading frame in subsequent exons, and permanent inactivation of collagen I expression. B: MEFs isolated from Col1a1f/f mice have deletion of
collagen I expression after AdCre, whereas cells treated with AdGFP or WT Col1a1 MEFs treated with AdGFP or AdCre have normal expression of collagen I by
immunoblot analysis. C: Lung epithelial cell-speciﬁc and permanent deletion of Col1a1 is achieved with the use of transgenic mice that carry the SPC-rtTA and
tetO-Cre. Triple transgenic SPC-rtTA/tetO-Cre/Col1a1f/f mice are abbreviated SCcol. The SPC promoter yields rtTA expression speciﬁcally within lung epithelial
cells, in the presence of doxycycline, rtTA activates the tetO-CMV promoter, leading to expression of cre recombinase and permanent deletion of DNA ﬂanked
by loxP sites. Deletion within lung epithelial cells is conﬁrmed by PCR with the use of primers that encompass the ﬂoxed region. Intact ﬂoxed Col1a1 yields
a 2.2-kb PCR product, and removal of the ﬂoxed Col1a1 yields a 0.5-kb PCR product. D and E: Uninjured lungs from SCcol (E) mice have normal histology
compared with littermate genotype control mice (D), by H&E staining. F: AECs from SCcol mice have diminished EMT-induced expression of collagen I by
immunoblot analysis compared with AECs from littermate control mice lacking one of the three transgenes. Primary lung ﬁbroblasts from SCcol mice have
similar collagen I expression compared with control lung ﬁbroblasts, verifying robust lung epithelial-speciﬁc deletion of Col1a1. Original magniﬁcation: 200
(D and E). AdCre, adenoviral-mediated expression of Cre; AdGFP, adenovirus expressing green ﬂuorescent protein; AEC, Alveolar epithelial cell; Col1a1,
collagen, type I, alpha 1; Ctrl, control; EMT, epithelial-mesenchymal transition; Fib, ﬁbroblast; MEF, murine embryonic ﬁbroblast; SPC-rtTA, surfactant
proteins-C promoter-reverse tetracycline transactivator; tetO-Cre, tetO-cytomegalovirus promoter-Cre recombinase; WT, wild-type.
AEC-Derived Collagen I Promotes Fibrosisthrough production and activation of endogenous
TGF-b1.24,42 AECs from SCcol mice expressed signiﬁcantly
reduced levels of collagen I after FN-mediated EMTs
compared with littermate control AECs (Figure 1F and
Supplemental Figure S2B). Lung ﬁbroblasts from SCcol mice
showed similar levels of collagen I as control lung ﬁbroblasts.
Thus, SCcol mice have robust lung epithelial cell-speciﬁc loss
of Col1a1. As expected SCcol mice have normal histology
(Figure 1, D and E) and physiology (Table 1) because lung
epithelial cells express little to no collagen I under physio-
logical conditions.14,24
Mice with Lung Epithelial Cell Deletion of Col1a1 Have
Abnormal Response to Injury
Groups of SCcol mice and littermate control mice lacking at
least one of the transgenes were given intratracheal saline orThe American Journal of Pathology - ajp.amjpathol.orgbleomycin. Genotype control mice developed robust ﬁbrosis
after bleomycin, visualized by trichrome and H&E staining.
In contrast, SCcol lungs appeared injured but had less ﬁbrosis
(Figure 2A and Supplemental Figure S3, A and B), resulting
in similar physiological impairment (Supplemental Table
S1). Immunoblot analysis of lung lysates indicated that
control mice have increased levels of collagen I in response to
bleomycin, whereas collagen I up-regulation was attenuated
in SCcol mice (Figure 2B and Supplemental Figure S4).
Hydroxyproline analysis also showed a robust increase in
collagen deposition in bleomycin-injured control mice and an
attenuated response in SCcol mice (Figure 2C).
Surprisingly, a trend was observed for more death in the
SCcol mice after bleomycin treatment than in the genotype
control mice. No deaths were found in either saline treat-
ment group (Figure 3A). To determine whether loss of
collagen deposition in SCcol mice led to increased or1563
Table 1 Baseline Physiology of Littermate Control and SCcol
mice
Control SCcol P value
IC (mL) 0.473  0.027 0.467  0.017 0.83
VC (mL) 0.562  0.034 0.559  0.019 0.93
ERV (mL) 0.089  0.009 0.092  0.003 0.73
FRC (mL) 0.586  0.017 0.575  0.012 0.64
TLC (mL) 1.059  0.038 1.042  0.029 0.71
RV (mL) 0.497  0.016 0.483  0.013 0.53
Cch (mL/cm H2O) 0.034  0.002 0.034  0.002 0.82
Values indicate means  SEM. n Z 9 to 10 per group.
Cch, chord compliance; ERV, expiratory reserve capacity; FRC, functional
reserve capacity; IC, inspiratory capacity; RV, residual volume; SCcol, triple
transgenic surfactant proteins-C promoter-reverse tetracycline transactivator/
tetO-cytomegalovirus promoter-Cre recombinase/homozygous ﬂoxed colla-
gen, type I, alpha 1; TLC, total lung capacity; VC, vital capacity.
Figure 2 Lung epithelial cell-derived type I collagen contributes to
ﬁbrogenesis. A: Lung sections from littermate control and SCcol mice 3
weeks after bleomycin injection, stained with H&E and trichrome. Original
magniﬁcation, 100. Genotype control mice have robust ﬁbrosis compared
with SCcol mice. B: Whole lung lysate from mice 3 weeks after treatment
with saline or bleomycin was analyzed for collagen I by immunoblot
analysis. Control mice have robust induction of collagen I after bleomycin
compared with SCcol mice. C: Hydroxyproline assay from entire lungs 3
weeks after saline or bleomycin in SCcol (black bars) or littermate control
(white bars) mice. SCcol mice have less ﬁbrosis after bleomycin (n Z 6 to
15 per group). *P < 0.05 versus control bleomycin. Bleo, bleomycin; Sal,
saline; SCcol, triple transgenic surfactant proteins-C promoter-reverse
tetracycline transactivator/tetO-cytomegalovirus promoter-Cre recombi-
nase/homozygous ﬂoxed collagen, type I, alpha 1.
Yang et alsustained lung injury/inﬂammation wemeasured total protein
and cell count in the BAL ﬂuid. Genotype control mice and
SCcol mice have a similar approximate ﬁvefold increase in
BAL protein and an approximate threefold increase in BAL
cell count 1 week after bleomycin. However, 2 weeks after
bleomycin, control mice have a reduction in BAL protein and
cell count, whereas persistent elevation was observed in
SCcol mice (Figure 3, B and C).
Because the trend toward increased death in SCcol mice
may affect the differences observed in the hydroxyproline
and collagen I immunoblot analysis, we wanted to assess for
differences in collagen I production at a time point before
bleomycin-induced death. One week after bleomycin,
mRNA from whole lungs of genotype control mice and
SCcol mice had a similar increase in Col1a1 mRNA
compared with saline-treated mice (Figure 4A). However,
mRNA fromAECs isolated 1 week after bleomycin indicated
an increased expression of Col1a1 within control AECs and
a signiﬁcant attenuation within isolated SCcol AECs
(Figure 4B). Deletion of the ﬂoxed exons 2 to 5 resulted in
frameshift and early termination of translation; however,
transcription and generation of truncated Col1a1 mRNA
lacking exons 2 to 5 (Col1a1 Dex2-5) may still occur within
lung epithelial-derived cells. PCR primers were generated to
detect the presence of a truncated Col1a1 Dex2-5 mRNA in
which exon 1 is directly adjacent to exon 6. Indeed, mRNA
from lungs of bleomycin-treated SCcol mice showed the
presence of Col1a1 Dex2-5 mRNA, indicating transcription
of Col1a1 speciﬁcally within lung epithelial-derived cells
(Figure 4C). Collectively, these studies indicated bleomycin-
induced expression of Col1a1 within lung epithelial cells.
Furthermore, genotype control mice had small foci of
collagen I deposition 1 week after bleomycin, and this was
largely absent in SCcol mice (Supplemental Figure S5, A and
B). Several studies have shown soluble procollagens in the
BAL ﬂuid of patients with ﬁbrotic lung disease.43e45 BAL
samples from SCcol and littermate control mice were
collected 1 week after bleomycin or saline treatment and were
analyzed by immunoblot for collagen I (Figure 4D and1564Supplemental Figure S6A). A dramatic increase was
observed in collagen I in the BAL ﬂuid of bleomycin-injured
control mice and attenuation in the SCcol mice treated with
bleomycin, indicating that accumulation of collagen I in the
BAL after bleomycin is dependent on the presence of an
intact Col1a1 gene within lung epithelial cells. Essentially,
no detectable collagen I was observed in the saline-treated
mice. We next wanted to determine whether deﬁcient
collagen accumulation could lead to attenuated collagen
signaling. DDR2 has been identiﬁed as a novel receptor
tyrosine kinase that uses type I collagen as its major ligand.46
Whole lung lysates were analyzed by immunoprecipitation
against DDR2, followed by immunoblot analysis for
phospho-tyrosine. As expected, genotype control mice had
increased phosphorylation of DDR2 in response toajp.amjpathol.org - The American Journal of Pathology
Figure 3 Lung epithelial cell-derived collagen I inhibits sustained lung
inﬂammation. A: Survival of littermate control (white circles; n Z 25) and
SCcol (black circles; nZ 18) mice after bleomycin. SCcol mice have a trend
toward less survival. B and C: BAL from control (white bars) and SCcol (black
bars) mice at 0, 7, and 14 days after bleomycin injury was analyzed for protein
(B), and cell count (C) shows that SCcol and control mice have similar increases
in proteins and cell count 1 week after bleomycin, whereas SCcol mice have
greater persistence of protein, nZ 5 to 7 per group. *P< 0.05 versus control
bleomycin. BAL, bronchoalveolar lavage; SCcol, triple transgenic surfactant
proteins-C promoter-reverse tetracycline transactivator/tetO-cytomegalovirus
promoter-Cre recombinase/homozygous ﬂoxed collagen, type I, alpha 1.
AEC-Derived Collagen I Promotes Fibrosisbleomycin, whereas SCcol mice had attenuated DDR2
phosphorylation, indicating deﬁcient collagen signaling in
these mice (Figure 4E and Supplemental Figure S6, B and C).
Collectively, these results support an important contribution
of type I collagen by lung epithelial cells after lung injury.
AEC Activation Promotes Fibroblast Activation
An initial collagen deposition by epithelial cells may promote
activation and collagen production by lung ﬁbroblasts. PriorThe American Journal of Pathology - ajp.amjpathol.orgstudies of collagen signaling within cultured ﬁbroblasts are
limited because of signiﬁcant expression of collagen I in
the conﬁned space of the culture dish. To address this
problem we isolated lung ﬁbroblasts from Col1a1f/f mice.
AdCre-treated Col1a1f/f lung ﬁbroblasts were stimulated
with BAL from control and SCcol mice collected 1 week
after saline or bleomycin injury. Fifteen minutes after BAL
stimulation cells were lysed and analyzed for phospho-
DDR2. BAL from control mice injured with bleomycin
induced DDR2 phosphorylation, indicating the presence of
bioactive collagen. DDR2 phosphorylation was not induced
by BAL from SCcol mice (Figure 5A and Supplemental
Figure S7A). To determine the inﬂuence of type I collagen
signaling on ﬁbroblast extracellular matrix (ECM) produc-
tion, Col1a1f/f lung ﬁbroblasts were treated with AdCre to
delete Col1a1 or AdGFP as a control. Lung ﬁbroblasts with
Cre-mediated deletion of Col1a1 had decreased expression
of Col1a1, as expected, and some suppression of Col1a2,
Col3a1, and FN expression. Culturing Cre-treated Col1a1f/f
lung ﬁbroblasts in the presence of collagen I reversed the
effects of AdCre treatment, suggesting that the presence of
collagen I modestly enhances transcription of these genes
within lung ﬁbroblasts (Figure 5B). Treating WT or AdGFP-
treated Col1a1f/f cells with exogenous type I collagen had
little effect on the expression of these genes. Given the
unexpected sustained inﬂammation in SCcol mice after
bleomycin, AdGFP- and AdCre-treated Col1a1f/f lung
ﬁbroblasts were also analyzed for expression of several
inﬂammatory cytokines. Surprisingly, deletion of Col1a1 led
to increased expression of IL-1a, IL-1b, and tumor necrosis
factor a (Supplemental Figure S8A).
Activated AECs may secrete other factors that more
profoundly promote ﬁbroblast activation.We and others have
previously reported that primary AECs cultured on laminin or
MG maintain an AEC phenotype, whereas cells cultured on
provisional matrix proteins such as ﬁbrin and FN undergo
TGF-bemediated EMTs.24,42 Murine lung ﬁbroblasts (MLg)
were treated with CM from primary AECs cultured on MG
(AEC CM) or FN (EMT CM). EMT CM promoted ﬁbroblast
expression of collagen I, SMA, and FN compared with
ﬁbroblasts treated with AECCM (Supplemental Figure S8B).
Enhanced expression of a-SMA and collagen I by ﬁbroblasts
stimulated with EMT CM was conﬁrmed by immunoblot
analysis (Figure 5C and Supplemental Figure S7B). Lung
ﬁbroblasts treated with EMT CM had levels of collagen I and
SMA similar to TGF-b1estimulated lung ﬁbroblasts,
whereas ﬁbroblasts treated with AEC CM or plain media had
lower levels of collagen I and SMA. EMT CM did not
promote Smad2 phosphorylation consistent with our prior
observations that TGF-b production and activation in this
in vitro system is required for AEC EMTs, but the active
TGF-b remains attached to the ECM rather than being
secreted into the CM. We next wanted to conﬁrm that
production of the EMT-derived ﬁbroblast activating factor(s)
required TGF-bemediated AEC EMTs. TGF-b signaling
was inhibited in primary AECs undergoing EMTs with the1565
Figure 4 Lung epithelial cell-deletion of collagen I attenuates collagen I
accumulation acutely after bleomycin treatment. A: Whole lung mRNA was
analyzed for Col1a1 mRNA 1 week after bleomycin or saline, nZ 4 to 9. *P<
0.05 versus control saline. Difference between control (white bars) and SCcol
(black bars) bleo is not statistically signiﬁcant. PZ 0.3. B: mRNA from AECs
isolated 1 week after bleomycin or saline, n Z 4. yP < 0.01 versus control
saline; zP< 0.01 versus control bleomycin. C: Whole lung mRNA was analyzed
with primers speciﬁc for a truncated Col1a1mRNAmissing exons 2 to 5 (Col1a1
Dex2-5), forward primerbridged the adjacent exons 1 and6, and reverse primer
was within exon 8. Col1a1 Dex2-5 was detected in SCcol mice 1 week after
bleomycin, indicating native promoter activation and transcription of the
recombined Col1a1 gene within lung epithelial cells after bleomycin. D:
Immunoblot of 50 mL of a 1-mL BAL from littermate control and SCcol mice 1
week after saline or bleomycin. Bleomycin induces collagen I accumulation in
BAL of control mice. BAL of SCcol mice have less collagen I accumulation after
bleomycin. E: Oneweek after bleomycin, SCcolmice have attenuated activation
of the collagen receptor DDR2 observed by immunopreciptiation of whole lung
lysate for DDR2 followed by immunoblot analysis for phosphotyrosine.
Immunoblot of 1% of the whole lung lysate indicates increase in DDR2
expression after bleomycin in SCcol and control mice. AEC, alveolar epithelial
cell; BAL, bronchoalveolar lavage; Bleo, bleomycin; Ctrl, control; DDR2, dis-
coidin domain receptor 2; Sal, saline; SCcol, triple transgenic surfactant
proteins-C promoter-reverse tetracycline transactivator/tetO-cytomegalovirus
promoter-Cre recombinase/homozygous ﬂoxed collagen, type I, alpha 1.
Yang et aluse of 10 mmol/L TGF-b receptor (TGF-bR) kinase inhibitor
(SB431642) and by using Smad3-deﬁcient AECs. CM from
AECs treated with SB431542 and from Smad3-null
AECs had a diminished capacity to activate lung ﬁbroblasts1566(Figure 5D and Supplemental Figure S7C). Collectively,
these results suggest that TGF-b signaling is required for
AECs to produce/secrete the ﬁbroblast stimulating factor(s)
but that the secreted factor is not TGF-b itself.
To identify candidate TGF-beinduced, AEC-derived
ﬁbroblast-activating factors we used a mouse ﬁbroblast
pathway-speciﬁc reverse transcription-PCR array. mRNA
from AECs cultured on MG, FN, or FN plus TGF-bR
inhibition were compared. As expected, AECs cultured on
FN had marked up-regulation of collagen I, collagen III, and
SMA, and expression of these genes was suppressed by
TGF-bR inhibition. The highest expressed genes by AECs
on FN included several secreted proﬁbrotic proteins: CTGF,
thrombospondin, collagen III, and collagen I (Figure 5E and
Supplemental Table S2). Expression of these genes was
suppressed by inhibition of TGF-b signaling. Several of
these factors have been used as markers of ﬁbrotic ﬁbro-
blasts and have been shown to induce ﬁbroblast expression
of type I collagen, suggesting that ﬁbroblast-activating
factors secreted by activated lung epithelial cells may not
be limited to type I collagen.Discussion
These ﬁndings support a model in which lung epithelial
cells can acquire functions and protein expression that
overlap with activated ﬁbroblasts in response to injury. In
this model, injury leads to activation of the epithelial cells
which initiates secretion of matrix proteins early in response
to injury, and these proteins promote activation of ﬁbro-
blasts, leading to progressive ﬁbrosis. We found that acti-
vated lung epithelial cells produce collagen I and that
deletion of type I collagen within lung epithelial cells limits
ﬁbrosis. Several prior reports have suggested the ability of
lung epithelial cells to express type I collagen in vitro when
stimulated with TGF-b.24,47 Recent reports indicate that
deletion of the TGF-b receptor in either lung epithelial cells
or resident ﬁbroblasts leads to a similar attenuation of
ﬁbrosis in mouse models.33,48 These ﬁndings are in agree-
ment with at least one point from a recent report from Rock
et al,26 in which type II AECs were found to have an
approximately twofold induction in type I collagen 10 days
after bleomycin. Rock et al26 did not ﬁnd other evidence for
EMT, in contrast to several other reports that favored EMT
during lung ﬁbrosis. The differences among these reports
are likely because of differences in the fate-mapping
strategy. Studies favoring EMT labeled lung epithelial
cells broadly, whereas Rock et al26 initiated fate-mapping
within a subtotal population of type II AECs. Indeed
in vitro evidence is strong that a number of different lung
epithelial cell types can express type I collagen when acti-
vated.17,20,24,47,49 Further, the fraction of labeled type II
AECs was dramatically reduced after bleomycin injury in
Rock et al,26 suggesting that the dTomato reporter used in
that study might be toxic to injured cells as previouslyajp.amjpathol.org - The American Journal of Pathology
Figure 5 Alveolar epithelial cell-derived factors promote ﬁbroblast acti-
vation. A: DDR2 phosphorylation of collagen I-deleted ﬁbroblasts by BAL from
control and SCcol mice collected 1 week after saline or bleomycin injury. Cells
treated with 10 mg/mL exogenous type I collagen and cells treated with BAL
from bleomycin-injured control mice have induction of DDR2 phosphorylation.
B: Reverse transcription-PCR of primary lung ﬁbroblasts from Col1a1f/f mice
treated with AdGFP, AdCre, or AdCre plus exogenously added type I collagen
(collagen I-coated plus 10mg/mLadded tomedia). Loss of collagen I expression
led to reduction in expression of several ﬁbroblast activation markers; the
expression of these genes was restored by exogenous collagen. C: Immunoblot
of lung ﬁbroblasts stimulated with plain media, CM from AECs cultured on
Matrigel (AEC CM), CM from AECs cultured on FN (EMT CM), and media supple-
mented with 4 ng/mL TGF-b. TGF-b and EMT CM activate ﬁbroblast expression of
a-SMA and collagen I. TGF-b promotes smad2 phosphorylation but EMT CM does
not.D: Immunoblot of lung ﬁbroblasts stimulatedwith plainmedia, CM fromWT
AECs cultured on FN (WT CM), smad3-null AECs (Sm3-CM) cultured on FN, andWT
AECs cultured on FN with addition of TGFb receptor inhibitor SB431542 (SB), 10
mmol/L (WTþ SB CM). E: Mouse ﬁbrosis reverse transcription-PCR array of AECs
cultured on Matrigel, FN, or FN with addition of SB. Expression of genes on FN
versusMatrigel (black) andFNwith SBversusMatrigel (red) areshown.Blue lines
indicate ﬁvefold differential expression. Several genes of interest are indicated.
AdCre, adenovirus expressing Cre; AdGFP adenovirus expressing green ﬂuores-
cent protein; AEC, alveolar epithelial cell; BAL, bronchoalveolar lavage; Bleo,
bleomycin; CM, conditionedmedia; Col I, type I collagen; Col1a1f/f, homozygous
ﬂoxedCol1a1; Col1a2, collagen, type I, alpha2; Col3a1, collagen, type III, alpha
1; ctgf, connective tissue growth factor; Ctrl, control; DDR2, discoidin domain
receptor-2; EMT, epithelial-mesenchymal transition; FN, ﬁbronectin; GAPDH,
glyceraldehyde phosphate dehydrogenase; lox, lysyl oxidase; Sal, saline; SB,
transforming growth factor b receptor inhibitor SB431542; SCcol, triple trans-
genic surfactant proteins-C promoter-reverse tetracycline transactivator/tetO-
cytomegalovirus promoter-Cre recombinase/homozygous ﬂoxed collagen,
type I, alpha 1; SMA, smooth muscle actin; sma, smooth muscle actin; TGF-b,
transforming growth factor b; tsp, thrombospondin; WT, wild-type.
AEC-Derived Collagen I Promotes Fibrosissuggested50 or that a plastic stem cell-like population capable
of regenerating the epithelium and up-regulating mesen-
chymal proteins during injury was not labeled. A consensus
deﬁnition of EMT has been elusive, and demonstrating anThe American Journal of Pathology - ajp.amjpathol.orgimportant contribution of proteins typically associated with
activated ﬁbroblasts may not be sufﬁcient to prove EMTs.
However, this approach may lead to a better understanding
of the functions of different cell types during ﬁbrogen-
esis, which may ultimately move the ﬁeld beyond this
controversy.
One critical limitation of a fate-mapping/costaining ap-
proach is the descriptive nature of the ﬁndings as opposed to
a functional analysis. We found that epithelial cell-derived
type I collagen affects both the overall amount of ﬁbrosis
and may have an effect on survival through regulating the
lung injury response. Some of this effect may be through
collagen-mediated cell signaling. We found that type I
collagen is produced quickly in response to injury and leads
to activation of the collagen signaling acutely after bleo-
mycin injury. Indeed, there is mounting evidence that col-
lagen signaling has important functions in inﬂammation and
ﬁbrogenesis.51,52 We used phosphorylation of the ﬁbroblast
collagen receptor, DDR2, as an indicator of epithelial cell-
derived collagen signaling on neighboring ﬁbroblasts.
In vitro, we found collagen-dependent activation of ﬁbro-
blasts (Figure 5). Deleting endogenous collagen expression
resulted in attenuated expression of several ECM genes, and
addition of exogenous collagen restored expression of these
genes (Figure 5B). These studies suggest the presence of
a collagen signaling pathway, leading to augmented ﬁbro-
blast production of ECM. It is unclear whether the cellular
source of collagen I is important in determining this
response in vivo, but differences in the timing and locali-
zation of collagen production after injury are potentially
important. We are currently investigating the role of speciﬁc
collagen receptors in regulating this response. Several
studies support an inﬂuence of DDR2 activation on ﬁbro-
blast function and that collagen I can signal through other
cell surface receptors.46 If type I collagen indeed promotes
further production of type I collagen, as our data suggest,
then epithelial cells may represent an important early source
of collagen I necessary for progressive ﬁbrosis. Thus, the
contribution of type I collagen from different cell types is
unlikely to be a simple sum calculation.
Deletion of type I collagen within lung epithelial cells
surprisingly promotes sustained lung inﬂammation after
bleomycin injury. These ﬁndings suggest that removing
a signiﬁcant source of type I collagen impairs the lungs
ability to replace the damaged normal matrix with a ﬁbrotic
matrix, leading to prolonged inﬂammation. The bleomycin
model is often criticized as a poor model of IPF in part
because of the robust inﬂammation that occurs after bleo-
mycin contrasted with the paucity of inﬂammation in
IPF.53,54 However, ﬁbrogenesis often occurs in the context
of acute and chronic inﬂammation, and factors produced
during the injury/inﬂammation phase are thought to facili-
tate the ﬁbrogenic phase by promoting ﬁbroblast activa-
tion.1,55 Our data suggest that factors produced during the
ﬁbrogenic phase, particularly collagen I, may regulate ter-
mination of the injury/inﬂammatory phase. As mentioned,1567
Yang et alsome evidence supports an anti-inﬂammatory role for type I
collagen. Indeed we found that deleting type I collagen
within primary lung ﬁbroblasts augments expression of
several inﬂammatory cytokines, suggesting autocrine and
paracrine inhibition of inﬂammatory cytokine expression
through type I collagen signaling. Our results may thus
translate better to inﬂammatory ﬁbrotic disease rather than
IPF and suggest that targeting collagen production after
robust lung injury must be taken with caution.
This study used type I collagen as a prototypical secreted
mesenchymal protein that is critical for ﬁbrogenesis, but
activated lung epithelial cells likely produce and secrete
other mesenchymal proteins that may promote ﬁbroblast
activation. We found that AECs have high expression of
a number of mesenchymal genes, including CTGF, ﬁbrillar
collagens, and thrombospondin. CTGF expression is in-
creased within ﬁbroblasts in patients with IPF.56 CTGF
expression is induced by TGF-b in a number of ﬁbroblast
cell lines and studies that used a CTGF-promoter GFP
transgenic reporter mouse reported CTGF promoter activity
exclusively within activated ﬁbroblasts57 in a model of skin
ﬁbrosis. CTGF has thus been used as an effective marker of
an activated, ﬁbrotic ﬁbroblast.58 CTGF expression has been
found within lung epithelial cells and endothelial cells
during ﬁbrogenesis and has been used as a marker of EMTs,
but the functional importance of epithelial cell-derived
CTGF has not been reported.59,60 Inhibition of CTGF has
been shown to attenuate ﬁbrosis in animal models.61,62
Thrombospondin expression has also been used as a
marker of ﬁbrogenic cells, and thrombospondin is thought
to enable activation of latent TGF-b, potentially promoting
ﬁbroblast activation. A recent report however found that
thrombospondin-null mice are not protected from
bleomycin-induced ﬁbrosis.63 In addition to type I collagen,
type III collagen is often used as a marker of activated
ﬁbroblasts, and mice with deletion of type III collagen have
impaired type I collagen ﬁbrillogenesis.64
Future studies that use this more functional approach may
help resolve controversies from descriptive fate-mapping
studies. The contribution of collagen I from other cell types
can be pursued in future studies, and epithelial cell-speciﬁc
deletion of other genes typically associated with activated
ﬁbroblasts (collagen III, ﬁbroblast-speciﬁc protein, SMA,
CTGF, etc) could be applied to better understand the
contribution of epithelial cell activation to ﬁbrogenesis. We
used PCR primers to speciﬁcally detect the presence of
a truncated Col1a1 mRNA (with exon 1 directly adjacent to
exon 6), indicating lung epithelial cell-speciﬁc origin of this
important ﬁbrotic protein. We cannot exclude the possibility
that translation of this modiﬁed mRNA results in a truncated
polypeptide affecting epithelial cell phenotype, but this
limitation does not affect the overall conclusion that acti-
vated epithelial cells are actively expressing Col1a1. This
PCR approach does not enable histological localization of
the epithelial-derived cells with activation of the Col1a1.
This approach importantly uses the intact native promoter1568rather than reporter transgenes with a fragment of the
promoter. This is important because different cell types
often activate transcription of the same genes by using
different promoter regions, some of which are distant from
the transcriptional start site.65,66 Expression of mesen-
chymal proteins from nontraditional cell types may use
previously uncharacterized promoter regions. Future studies
will investigate differences between epithelial cells and
ﬁbroblasts in promoter activation sites. A more complete
understanding of cellular contributions to progressive
ﬁbrogenesis may lead to new targets for potential thera-
peutic intervention.Acknowledgments
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